Based on the Likert scale, most patients with atopic dermatitis (AD) using baricitinib reported being either “satisfied” (76%) or “very satisfied” (18%). Most patients with atopic dermatitis (AD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback